<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417989</url>
  </required_header>
  <id_info>
    <org_study_id>CEP179/Z25</org_study_id>
    <nct_id>NCT00417989</nct_id>
  </id_info>
  <brief_title>Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy</brief_title>
  <acronym>STAR3</acronym>
  <official_title>The STAR 3 Study - A Prospective, Randomized, Two-Arm Study to Compare the Efficacy of the MiniMed Paradigm REAL-Time System Versus Multiple Daily Injections (MDI) in Subjects Naïve to Insulin Pump Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for
      subjects in the &quot;722 Group&quot; is greater than that for subjects in the &quot;Control (MDI) Group&quot;.

      Secondary Outcomes: Incidence and frequency of severe hypoglycemia; Measure of glycemic
      variability, Area Under the Curve (AUC); Quality of Life; and Health Economic Outcomes (MRU)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glycemic control remains a significant challenge for adult, adolescent and pediatric Type 1
      diabetics. The current first line standard of care continues to be MDI therapy utilizing a
      long acting analog insulin. Continuous Glucose Monitoring (CGMS) is currently used by
      clinicians to record continuous, retrospective glucose measurements, which aid in
      identification of glycemic excursion patterns. This data is then used to make future therapy
      change recommendations. The MiniMed Paradigm REAL-Time System transmits real-time glucose
      measurements to the insulin pump every 5 minutes, allowing users to view their current
      glucose values, as well as to review glycemic excursions and trends over a 24-hour period.
      Additionally, data can be downloaded from the monitor to a personal computer, using
      appropriate software, so that the patient and physician can see a complete picture of glucose
      trends over time. The System will also alert users of high and low glucose levels, and allow
      subjects and their clinicians to treat to a therapeutic target HbA1c under carefully
      monitored conditions.

      Subjects wearing the MiniMed Paradigm REAL-Time System will be compared to subjects that
      continue on their current MDI therapy, that includes a long acting analog insulin, over a 12
      month period to evaluate changes in glycemic control (HbA1c).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1c From Baseline to 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change is defined as A1c at Week 52 minus A1c at Baseline in each study arm. The difference between the change in each group will then be analyzed. A1c measure is defined as the percent of glycated hemoglobin using one standardized assay for all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Frequency of Severe Hypoglycemia From Baseline to Week 52;</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Severe Hypoglycemia is defined as a hypoglycemic episode absolutely requiring assistance from another person and preferably accompanied by a confirmatory Blood Glucose (BG) by finger stick of less than 50 mg/dL (2.8 mmol/L). The frequency evaluates the total number of events. This will be analyzed and compared between the two study arms from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Difference in Rate of Severe Hypoglycemia Events Between Study Arms From Baseline to Week 52</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Severe Hypoglycemia is defined as a hypoglycemic episode absolutely requiring assistance from another person and preferably accompanied by a confirmatory BG by finger stick of less than 50 mg/dL (2.8 mmol/L). The rate evaluates the number of participants that experienced at least one severe hypoglycemia event and compares this number between the two study arms from Baseline to week 52. This measure identifies the rate or frequency of unique participant events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 52;</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Hypoglycemia is defined as a recorded blood glucose event &lt;70mg/dL. The amount of time spent below this parameter will be analyzed and compared between groups from Baseline to Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 52</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Hyperglycemia is defined as a recorded blood glucose event &gt; 180 mg/dL. The amount of time spent above this parameter will be analyzed and compared between groups from Baseline to Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Hypoglycemia Fear Scale (HFS), Overall Score</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Difference of Baseline and 52 Weeks in Hypoglycemia Fear Scale (HFS) Overall Score between the two study arms (adult subjects only) is presented. Both baseline and 52 weeks scores range from 0-100, with lower scores suggest higher satisfaction. Therefore, a negative number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Outcome</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Health Economic Outcome was a cost-effectiveness analysis combining estimates from the trial and the literature to populate the previously validated Center for Outcomes Research (CORE) Diabetes Model. Results represent the use of 3-day sensors. This analysis was restricted to only adult subjects (Age 19 to 70), therefore the number of participant analyzed is different. The goal was to estimate the long term cost effectiveness of Sensor Augmented Pump therapy from the perspective of the US health care system. The unit of measurement was cost in $ per year for sensor augmented pump group and MDI group. No formal statistical analysis was planned or performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Short Form-36 (SF-36v2™), General Health</measure>
    <time_frame>Baseline and 52 Weeks</time_frame>
    <description>Difference of Baseline and 52 Weeks in Short Form-36 (SF-36v2™), General Health, between the two study arms (adult subjects only) is presented. Both baseline and 52 weeks scores range from 0-100, with higher scores suggest higher satisfaction. Therefore, a positive number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy</measure>
    <time_frame>Baseline and 52 Weeks</time_frame>
    <description>Difference of Baseline and 52 Weeks in Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction with Type of Insulin Therapy, between the two study arms is presented. Both baseline and 52 weeks scores range from 0-100, with higher scores suggest higher satisfaction. Therefore, a positive number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>722 sensor augmented pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Daily Injections (MDI)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiniMed Paradigm REAL-Time System</intervention_name>
    <description>Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter</description>
    <arm_group_label>722 sensor augmented pump</arm_group_label>
    <other_name>Medtronic Paradigm REAL-Time System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 7 to 70 years

          -  Has been treated by the Principal Investigator or referring physician within the same
             practice for at least six months prior to screening

          -  Is fluent in speaking, reading and understanding English

          -  Has Type 1 diabetes mellitus, diagnosed by c-peptide, insulin antibodies, or prior
             documented DKA, or by a clinical picture consistent with Type 1 diabetes and excluding
             type 2 diabetes i.e. - previous ketosis as evidenced by laboratory evidence of urine
             ketones or alteration in bicarbonate levels with corresponding increased glucose
             levels, diagnosed at least 6 months prior to study entry, or has a fasting C-peptide
             that meet criteria of 110% of lower limit of normal or 200% of lower limit of normal
             in the presence of renal insufficiency (creatinine clearance &lt; 50ml/min) at screening

          -  Is insulin infusion pump naїve or has not used an insulin pump within the last three
             years

          -  Currently is treated with insulin administration by injection &gt; (greater or equal to)
             three (3) times daily and therapy has included the use of a long acting analog insulin
             for at least the previous 3 months prior to screening

          -  Performs fingerstick blood glucose (BG) testing an average of four times per day in
             the 30 days prior to screening

          -  Within 6 months prior to study entry and at Screening Visit 1, subject has a
             documented A1c level =/&gt; 7.4% and =/&lt; 9.5%

        Exclusion Criteria:

          -  Is pregnant or planning to become pregnant during the course of the study

          -  Has suffered two or more documented events of severe hypoglycemia without warning of
             impending low glucose levels, within the previous 12 months

          -  Currently using oral or injectable steroids or immunosuppressant medications

          -  Use of any other pharmaceutical agent, other than insulin to treat diabetes, within
             the three months prior to screening;

          -  Has a current history of alcohol or drug abuse

          -  Has a history of myocardial infarction, unstable angina, coronary artery bypass
             surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular
             accident (CVA), or thromboembolic disease in the 3 months prior to screening

          -  Has uncontrolled hypertension (diastolic blood pressure &gt;100 mmHg and/or sustained
             systolic level [3 successive readings] &gt; 160). Subjects who are taking
             antihypertensive medication will not be excluded provided they are maintained at a
             stable dose for 3 months prior to screening

          -  Has serious or unstable medical or psychological conditions (e.g., eating disorders,
             clinical depression, anxiety disorder) which, in the opinion of the Investigator,
             would compromise the subject's safety or successful participation in the study

          -  Is undergoing renal dialysis, including hemodialysis and continuous ambulatory
             peritoneal dialysis (CAPD)

          -  Has evidence of any allergic dermatological condition (e.g., severe adhesive
             sensitivity)

          -  Has recurrent episodes of skin infections or history of staphylococcus infection
             carrier state

          -  Has potential for lack of compliance or any other issue that may preclude the subject
             from satisfactory participation in the study, based on Investigatory judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William V Tamborlane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott W Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Minimed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County (CHOC)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92864-3874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, University of Colorado</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Institute (DRI)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions, Inc.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-America Diabetes Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Diabetes Endocrinology Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota International Diabetes Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of St. Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Diabetes Research Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes and Obesity Center, East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Diabetes Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Health West</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research, Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Center Memorial Hospital of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7M5L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>December 24, 2010</results_first_submitted>
  <results_first_submitted_qc>February 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2011</results_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycemic control</keyword>
  <keyword>Sensor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>722 Sensor Augmented Pump</title>
          <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
        </group>
        <group group_id="P2">
          <title>Multiple Daily Injection (MDI)</title>
          <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244">Intent to Treat include safety population &amp; subjects with baseline &amp; 1 post baseline A1C measurement</participants>
                <participants group_id="P2" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>722 Sensor Augmented Pump</title>
          <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
        </group>
        <group group_id="B2">
          <title>Multiple Daily Injection (MDI)</title>
          <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="241"/>
            <count group_id="B3" value="485"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="17.47"/>
                    <measurement group_id="B2" value="31.50" spread="16.50"/>
                    <measurement group_id="B3" value="31.90" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 19 and 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in A1c From Baseline to 52 Weeks</title>
        <description>Change is defined as A1c at Week 52 minus A1c at Baseline in each study arm. The difference between the change in each group will then be analyzed. A1c measure is defined as the percent of glycated hemoglobin using one standardized assay for all subjects.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Change in A1c From Baseline to 52 Weeks</title>
          <description>Change is defined as A1c at Week 52 minus A1c at Baseline in each study arm. The difference between the change in each group will then be analyzed. A1c measure is defined as the percent of glycated hemoglobin using one standardized assay for all subjects.</description>
          <units>Percent glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.84"/>
                    <measurement group_id="O2" value="-0.2" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null - There is no treatment group difference in A1c change from baseline to Week 52. Calculated that the enrollment of 495 patients would provide a power of 90% to detect an absolute difference of 0.35 percentage points in the primary outcome, assuming a SD of 1.2%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Superiority test with margin of 0.35</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>Confidence Interval 95%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANVOCA is adjusted by study group, gender, pooled site, continuous age, duration of diabetes, BMI, and Baseline glycated hemoglobin level (A1C)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Frequency of Severe Hypoglycemia From Baseline to Week 52;</title>
        <description>Severe Hypoglycemia is defined as a hypoglycemic episode absolutely requiring assistance from another person and preferably accompanied by a confirmatory Blood Glucose (BG) by finger stick of less than 50 mg/dL (2.8 mmol/L). The frequency evaluates the total number of events. This will be analyzed and compared between the two study arms from baseline to week 52.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Frequency of Severe Hypoglycemia From Baseline to Week 52;</title>
          <description>Severe Hypoglycemia is defined as a hypoglycemic episode absolutely requiring assistance from another person and preferably accompanied by a confirmatory Blood Glucose (BG) by finger stick of less than 50 mg/dL (2.8 mmol/L). The frequency evaluates the total number of events. This will be analyzed and compared between the two study arms from baseline to week 52.</description>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Difference in Rate of Severe Hypoglycemia Events Between Study Arms From Baseline to Week 52</title>
        <description>Severe Hypoglycemia is defined as a hypoglycemic episode absolutely requiring assistance from another person and preferably accompanied by a confirmatory BG by finger stick of less than 50 mg/dL (2.8 mmol/L). The rate evaluates the number of participants that experienced at least one severe hypoglycemia event and compares this number between the two study arms from Baseline to week 52. This measure identifies the rate or frequency of unique participant events.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Difference in Rate of Severe Hypoglycemia Events Between Study Arms From Baseline to Week 52</title>
          <description>Severe Hypoglycemia is defined as a hypoglycemic episode absolutely requiring assistance from another person and preferably accompanied by a confirmatory BG by finger stick of less than 50 mg/dL (2.8 mmol/L). The rate evaluates the number of participants that experienced at least one severe hypoglycemia event and compares this number between the two study arms from Baseline to week 52. This measure identifies the rate or frequency of unique participant events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 52;</title>
        <description>Hypoglycemia is defined as a recorded blood glucose event &lt;70mg/dL. The amount of time spent below this parameter will be analyzed and compared between groups from Baseline to Week 52.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 52;</title>
          <description>Hypoglycemia is defined as a recorded blood glucose event &lt;70mg/dL. The amount of time spent below this parameter will be analyzed and compared between groups from Baseline to Week 52.</description>
          <units>mmol/dl*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.66"/>
                    <measurement group_id="O2" value="0.0" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No power calculation based on this endpoint. Results will be calculated on testing for statistical difference between arms.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANVOCA is adjusted by study group, gender, pooled site, continuous age, duration of diabetes, BMI, and Baseline AUC</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 52</title>
        <description>Hyperglycemia is defined as a recorded blood glucose event &gt; 180 mg/dL. The amount of time spent above this parameter will be analyzed and compared between groups from Baseline to Week 52.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 52</title>
          <description>Hyperglycemia is defined as a recorded blood glucose event &gt; 180 mg/dL. The amount of time spent above this parameter will be analyzed and compared between groups from Baseline to Week 52.</description>
          <units>mmol/dl*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="19.31"/>
                    <measurement group_id="O2" value="-1.1" spread="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No power calculation based on this endpoint. Results will be calculated on testing for statistical difference between arms.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANVOCA is adjusted by study group, gender, pooled site, continuous age, duration of diabetes, BMI, and Baseline AUC</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Hypoglycemia Fear Scale (HFS), Overall Score</title>
        <description>Difference of Baseline and 52 Weeks in Hypoglycemia Fear Scale (HFS) Overall Score between the two study arms (adult subjects only) is presented. Both baseline and 52 weeks scores range from 0-100, with lower scores suggest higher satisfaction. Therefore, a negative number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Adult population (18 and older) only</population>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Hypoglycemia Fear Scale (HFS), Overall Score</title>
          <description>Difference of Baseline and 52 Weeks in Hypoglycemia Fear Scale (HFS) Overall Score between the two study arms (adult subjects only) is presented. Both baseline and 52 weeks scores range from 0-100, with lower scores suggest higher satisfaction. Therefore, a negative number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
          <population>Adult population (18 and older) only</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="16.04"/>
                    <measurement group_id="O2" value="-2.4" spread="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.760</ci_lower_limit>
            <ci_upper_limit>-3.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Economic Outcome</title>
        <description>Health Economic Outcome was a cost-effectiveness analysis combining estimates from the trial and the literature to populate the previously validated Center for Outcomes Research (CORE) Diabetes Model. Results represent the use of 3-day sensors. This analysis was restricted to only adult subjects (Age 19 to 70), therefore the number of participant analyzed is different. The goal was to estimate the long term cost effectiveness of Sensor Augmented Pump therapy from the perspective of the US health care system. The unit of measurement was cost in $ per year for sensor augmented pump group and MDI group. No formal statistical analysis was planned or performed</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
MiniMed Paradigm REAL-Time System: Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injections (MDI)</title>
            <description>MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Health Economic Outcome</title>
          <description>Health Economic Outcome was a cost-effectiveness analysis combining estimates from the trial and the literature to populate the previously validated Center for Outcomes Research (CORE) Diabetes Model. Results represent the use of 3-day sensors. This analysis was restricted to only adult subjects (Age 19 to 70), therefore the number of participant analyzed is different. The goal was to estimate the long term cost effectiveness of Sensor Augmented Pump therapy from the perspective of the US health care system. The unit of measurement was cost in $ per year for sensor augmented pump group and MDI group. No formal statistical analysis was planned or performed</description>
          <units>$</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10,760"/>
                    <measurement group_id="O2" value="5,072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Short Form-36 (SF-36v2™), General Health</title>
        <description>Difference of Baseline and 52 Weeks in Short Form-36 (SF-36v2™), General Health, between the two study arms (adult subjects only) is presented. Both baseline and 52 weeks scores range from 0-100, with higher scores suggest higher satisfaction. Therefore, a positive number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
        <time_frame>Baseline and 52 Weeks</time_frame>
        <population>Adult population (18 and older) only</population>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Short Form-36 (SF-36v2™), General Health</title>
          <description>Difference of Baseline and 52 Weeks in Short Form-36 (SF-36v2™), General Health, between the two study arms (adult subjects only) is presented. Both baseline and 52 weeks scores range from 0-100, with higher scores suggest higher satisfaction. Therefore, a positive number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
          <population>Adult population (18 and older) only</population>
          <units>Participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="8.07"/>
                    <measurement group_id="O2" value="-0.3" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.75</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy</title>
        <description>Difference of Baseline and 52 Weeks in Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction with Type of Insulin Therapy, between the two study arms is presented. Both baseline and 52 weeks scores range from 0-100, with higher scores suggest higher satisfaction. Therefore, a positive number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
        <time_frame>Baseline and 52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>722 Sensor Augmented Pump</title>
            <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injection (MDI)</title>
            <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy</title>
          <description>Difference of Baseline and 52 Weeks in Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction with Type of Insulin Therapy, between the two study arms is presented. Both baseline and 52 weeks scores range from 0-100, with higher scores suggest higher satisfaction. Therefore, a positive number in the difference suggests higher satisfaction at 52 Weeks than Baseline.</description>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="25.61"/>
                    <measurement group_id="O2" value="-0.2" spread="21.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.53</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>722 Sensor Augmented Pump</title>
          <description>722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year</description>
        </group>
        <group group_id="E2">
          <title>Multiple Daily Injection (MDI)</title>
          <description>MDI arm: Continue with MDI using Lantus and NovoLog/NovoRapid for 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 8.0">Retinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac (Atypical) Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Gastroenteritis (Acute Gastroenteritis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Cellulitis (Cellulitis of Left Lower Leg)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula Fracture (Fracture of Left Lower Leg, Fibula at Ankle)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Skin Laceration (Traumatic Laceration to Dorsum of the Right Foot with extensor Hallucis Longus Tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Urethral Injury (Urethral Tear)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Limb Crushing Injury (Crush Injury to Right Lateral Thigh)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Hypoglycemia (Severe Hypoglycemia)</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Hypoglycemia (Severe Hypoglycemia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis (Ketoacidosis)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <description>Did not meet protocol criteria for DKA</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Did not meet protocol definition of Severe Hypoglycemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer (Left Breast Cancer: Invasive Ductal Adenocarcinoma)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope Vasovagal (Syncope Vasovagal Response)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis (Kidney Stones)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site bleeding/bruising/irritation/pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infusion/application site infection/abscess</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="88" subjects_affected="32" subjects_at_risk="244"/>
                <counts group_id="E2" events="56" subjects_affected="28" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="36" subjects_at_risk="244"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="241"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="37" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="241"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Lee, M.D.</name_or_title>
      <organization>Medtronic</organization>
      <phone>8185764204</phone>
      <email>scott.w.lee@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

